Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells
Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells
复制标题
DOI：
10.1007/s10875-010-9394-5
复制
发表时间：
2010-05-01
影响因子：
9.1
通讯作者：
Kaveri, Srini V.
中科院分区：
文献类型：
--
作者：
Maddur, Mohan S.;Othy, Shivashankar;Kaveri, Srini V.
由于CD4（+）CD25（+）FoxP3（+）调节性T细胞（T细胞）的缺陷或功能缺陷而导致的免疫稳态改变在几种自身免疫性疾病中很常见。因此，正在研究使TdR功能胜任的治疗策略。静脉注射免疫球蛋白（IVIG）越来越多地用于治疗各种自身免疫性和炎症性疾病。最近的研究表明，IVIG诱导T细胞扩增并增强其抑制功能。IVIG对TcG的这些作用与IVIG在自身免疫性疾病患者中的有益作用相关。因此，通过IVIG调节T细胞介导的自身免疫性疾病代表了一种新的作用模式，其解释了IVIG在T细胞介导的自身免疫性疾病中的治疗作用。然而，涉及IVIG介导的调节TdR的分子机制尚不清楚，需要进一步研究。
An altered immune homeostasis as a result of deficiency or defective function of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) is common in several autoimmune diseases. Hence, therapeutic strategies to render Tregs functionally competent are being investigated. Intravenous immunoglobulin (IVIG) is being increasingly used for the treatment of a wide range of autoimmune and inflammatory diseases. Recent studies have demonstrated that IVIG induces the expansion of Tregs and enhances their suppressive functions. These effects of IVIG on Tregs correlate with the beneficial effects of IVIG in patients with autoimmune diseases. Thus, modulation of Tregs by IVIG represents a novel mode of action that explains the therapeutic effects of IVIG in T cell-mediated autoimmune diseases. However, the molecular mechanisms involved in IVIG-mediated modulation of Tregs are unclear and need further investigation.